Rare Biomarkers Specimen Collection and Stabilization Market Size, Global Trends & Insights by 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Rare Biomarkers Specimen Collection and Stabilization Market Size Analysis

Global Rare Biomarkers Specimen Collection and Stabilization Market Introduction
By Type
1. Introduction
  1. Type By Value
2. Circulating Cell-Free DNA (ccfDNA)
  1. By Value
3. Circulating Tumor Cells (CTCs)
  1. By Value
4. Exosomes/Extracellular Vesicles
  1. By Value
By Product
1. Introduction
  1. Product By Value
2. Isolation Kits & Reagents
  1. By Value
3. Blood Collection Tubes
  1. By Value
4. Systems
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Non-Invasive Prenatal Testing (NIPT)
  1. By Value
3. Oncology
  1. By Value
4. Pharmacogenomics
  1. By Value
5. Transplant Rejection
  1. By Value
6. Cardiovascular Diseases
  1. By Value
7. Others
  1. By Value
By End-Users
1. Introduction
  1. End-Users By Value
2. Hospitals
  1. By Value
3. Perinatal Clinics
  1. By Value
4. Diagnostics Laboratories
  1. By Value
5. Research Institutes
  1. By Value
6. Others
  1. By Value

North America Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Circulating Cell-Free DNA (ccfDNA)
  1. By Value
3. Circulating Tumor Cells (CTCs)
  1. By Value
4. Exosomes/Extracellular Vesicles
  1. By Value
By Product
1. Introduction
  1. Product By Value
2. Isolation Kits & Reagents
  1. By Value
3. Blood Collection Tubes
  1. By Value
4. Systems
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Non-Invasive Prenatal Testing (NIPT)
  1. By Value
3. Oncology
  1. By Value
4. Pharmacogenomics
  1. By Value
5. Transplant Rejection
  1. By Value
6. Cardiovascular Diseases
  1. By Value
7. Others
  1. By Value
By End-Users
1. Introduction
  1. End-Users By Value
2. Hospitals
  1. By Value
3. Perinatal Clinics
  1. By Value
4. Diagnostics Laboratories
  1. By Value
5. Research Institutes
  1. By Value
6. Others
  1. By Value
U.S.
1. By Type
  1. Introduction
    1. Type By Value
  2. Circulating Cell-Free DNA (ccfDNA)
    1. By Value
  3. Circulating Tumor Cells (CTCs)
    1. By Value
  4. Exosomes/Extracellular Vesicles
    1. By Value
2. By Product
  1. Introduction
    1. Product By Value
  2. Isolation Kits & Reagents
    1. By Value
  3. Blood Collection Tubes
    1. By Value
  4. Systems
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Non-Invasive Prenatal Testing (NIPT)
    1. By Value
  3. Oncology
    1. By Value
  4. Pharmacogenomics
    1. By Value
  5. Transplant Rejection
    1. By Value
  6. Cardiovascular Diseases
    1. By Value
  7. Others
    1. By Value
4. By End-Users
  1. Introduction
    1. End-Users By Value
  2. Hospitals
    1. By Value
  3. Perinatal Clinics
    1. By Value
  4. Diagnostics Laboratories
    1. By Value
  5. Research Institutes
    1. By Value
  6. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Circulating Cell-Free DNA (ccfDNA)
  1. By Value
3. Circulating Tumor Cells (CTCs)
  1. By Value
4. Exosomes/Extracellular Vesicles
  1. By Value
By Product
1. Introduction
  1. Product By Value
2. Isolation Kits & Reagents
  1. By Value
3. Blood Collection Tubes
  1. By Value
4. Systems
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Non-Invasive Prenatal Testing (NIPT)
  1. By Value
3. Oncology
  1. By Value
4. Pharmacogenomics
  1. By Value
5. Transplant Rejection
  1. By Value
6. Cardiovascular Diseases
  1. By Value
7. Others
  1. By Value
By End-Users
1. Introduction
  1. End-Users By Value
2. Hospitals
  1. By Value
3. Perinatal Clinics
  1. By Value
4. Diagnostics Laboratories
  1. By Value
5. Research Institutes
  1. By Value
6. Others
  1. By Value
U.K.
1. By Type
  1. Introduction
    1. Type By Value
  2. Circulating Cell-Free DNA (ccfDNA)
    1. By Value
  3. Circulating Tumor Cells (CTCs)
    1. By Value
  4. Exosomes/Extracellular Vesicles
    1. By Value
2. By Product
  1. Introduction
    1. Product By Value
  2. Isolation Kits & Reagents
    1. By Value
  3. Blood Collection Tubes
    1. By Value
  4. Systems
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Non-Invasive Prenatal Testing (NIPT)
    1. By Value
  3. Oncology
    1. By Value
  4. Pharmacogenomics
    1. By Value
  5. Transplant Rejection
    1. By Value
  6. Cardiovascular Diseases
    1. By Value
  7. Others
    1. By Value
4. By End-Users
  1. Introduction
    1. End-Users By Value
  2. Hospitals
    1. By Value
  3. Perinatal Clinics
    1. By Value
  4. Diagnostics Laboratories
    1. By Value
  5. Research Institutes
    1. By Value
  6. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Circulating Cell-Free DNA (ccfDNA)
  1. By Value
3. Circulating Tumor Cells (CTCs)
  1. By Value
4. Exosomes/Extracellular Vesicles
  1. By Value
By Product
1. Introduction
  1. Product By Value
2. Isolation Kits & Reagents
  1. By Value
3. Blood Collection Tubes
  1. By Value
4. Systems
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Non-Invasive Prenatal Testing (NIPT)
  1. By Value
3. Oncology
  1. By Value
4. Pharmacogenomics
  1. By Value
5. Transplant Rejection
  1. By Value
6. Cardiovascular Diseases
  1. By Value
7. Others
  1. By Value
By End-Users
1. Introduction
  1. End-Users By Value
2. Hospitals
  1. By Value
3. Perinatal Clinics
  1. By Value
4. Diagnostics Laboratories
  1. By Value
5. Research Institutes
  1. By Value
6. Others
  1. By Value
China
1. By Type
  1. Introduction
    1. Type By Value
  2. Circulating Cell-Free DNA (ccfDNA)
    1. By Value
  3. Circulating Tumor Cells (CTCs)
    1. By Value
  4. Exosomes/Extracellular Vesicles
    1. By Value
2. By Product
  1. Introduction
    1. Product By Value
  2. Isolation Kits & Reagents
    1. By Value
  3. Blood Collection Tubes
    1. By Value
  4. Systems
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Non-Invasive Prenatal Testing (NIPT)
    1. By Value
  3. Oncology
    1. By Value
  4. Pharmacogenomics
    1. By Value
  5. Transplant Rejection
    1. By Value
  6. Cardiovascular Diseases
    1. By Value
  7. Others
    1. By Value
4. By End-Users
  1. Introduction
    1. End-Users By Value
  2. Hospitals
    1. By Value
  3. Perinatal Clinics
    1. By Value
  4. Diagnostics Laboratories
    1. By Value
  5. Research Institutes
    1. By Value
  6. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Circulating Cell-Free DNA (ccfDNA)
  1. By Value
3. Circulating Tumor Cells (CTCs)
  1. By Value
4. Exosomes/Extracellular Vesicles
  1. By Value
By Product
1. Introduction
  1. Product By Value
2. Isolation Kits & Reagents
  1. By Value
3. Blood Collection Tubes
  1. By Value
4. Systems
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Non-Invasive Prenatal Testing (NIPT)
  1. By Value
3. Oncology
  1. By Value
4. Pharmacogenomics
  1. By Value
5. Transplant Rejection
  1. By Value
6. Cardiovascular Diseases
  1. By Value
7. Others
  1. By Value
By End-Users
1. Introduction
  1. End-Users By Value
2. Hospitals
  1. By Value
3. Perinatal Clinics
  1. By Value
4. Diagnostics Laboratories
  1. By Value
5. Research Institutes
  1. By Value
6. Others
  1. By Value
UAE
1. By Type
  1. Introduction
    1. Type By Value
  2. Circulating Cell-Free DNA (ccfDNA)
    1. By Value
  3. Circulating Tumor Cells (CTCs)
    1. By Value
  4. Exosomes/Extracellular Vesicles
    1. By Value
2. By Product
  1. Introduction
    1. Product By Value
  2. Isolation Kits & Reagents
    1. By Value
  3. Blood Collection Tubes
    1. By Value
  4. Systems
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Non-Invasive Prenatal Testing (NIPT)
    1. By Value
  3. Oncology
    1. By Value
  4. Pharmacogenomics
    1. By Value
  5. Transplant Rejection
    1. By Value
  6. Cardiovascular Diseases
    1. By Value
  7. Others
    1. By Value
4. By End-Users
  1. Introduction
    1. End-Users By Value
  2. Hospitals
    1. By Value
  3. Perinatal Clinics
    1. By Value
  4. Diagnostics Laboratories
    1. By Value
  5. Research Institutes
    1. By Value
  6. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Circulating Cell-Free DNA (ccfDNA)
  1. By Value
3. Circulating Tumor Cells (CTCs)
  1. By Value
4. Exosomes/Extracellular Vesicles
  1. By Value
By Product
1. Introduction
  1. Product By Value
2. Isolation Kits & Reagents
  1. By Value
3. Blood Collection Tubes
  1. By Value
4. Systems
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Non-Invasive Prenatal Testing (NIPT)
  1. By Value
3. Oncology
  1. By Value
4. Pharmacogenomics
  1. By Value
5. Transplant Rejection
  1. By Value
6. Cardiovascular Diseases
  1. By Value
7. Others
  1. By Value
By End-Users
1. Introduction
  1. End-Users By Value
2. Hospitals
  1. By Value
3. Perinatal Clinics
  1. By Value
4. Diagnostics Laboratories
  1. By Value
5. Research Institutes
  1. By Value
6. Others
  1. By Value
Brazil
1. By Type
  1. Introduction
    1. Type By Value
  2. Circulating Cell-Free DNA (ccfDNA)
    1. By Value
  3. Circulating Tumor Cells (CTCs)
    1. By Value
  4. Exosomes/Extracellular Vesicles
    1. By Value
2. By Product
  1. Introduction
    1. Product By Value
  2. Isolation Kits & Reagents
    1. By Value
  3. Blood Collection Tubes
    1. By Value
  4. Systems
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Non-Invasive Prenatal Testing (NIPT)
    1. By Value
  3. Oncology
    1. By Value
  4. Pharmacogenomics
    1. By Value
  5. Transplant Rejection
    1. By Value
  6. Cardiovascular Diseases
    1. By Value
  7. Others
    1. By Value
4. By End-Users
  1. Introduction
    1. End-Users By Value
  2. Hospitals
    1. By Value
  3. Perinatal Clinics
    1. By Value
  4. Diagnostics Laboratories
    1. By Value
  5. Research Institutes
    1. By Value
  6. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Rare Biomarkers Specimen Collection and Stabilization Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Koneksa Health
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
QIAGEN
Hoffmann-La Roche Ltd
Thermo Fisher Scientific Inc.
Eurofins Scientific
Bio-Rad Laboratories, Inc.
Agilent Technologies, Inc.
Merck KGaA
Siemens Healthcare Private Limited
BD
Illumina, Inc.
Beckman Coulter, Inc.
Oxford Nanopore Technologies plc.
Guardant Health
Avidity Bioscience

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment